Monitor for subsequent Form 4 filings to confirm execution of the sale. The filing extends a recent insider selling pattern, which may signal reduced conviction at current valuation levels. Given the company's high analyst bullish consensus (93%), the selling could create short-term overhang.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $114.20entry
- T+1 · 5mo ago −0.60%α −0.47% · $113.51
- T+5 · 4mo ago +4.41%α +4.15% · $119.24
- T+20 · 4mo ago −7.84%α −5.65% · $105.25
- T+60 · 8w ago +1.41%α −1.55% · $115.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Officer Bruce N. Jacobs filed a Form 144 notice of intent to sell 77,109 shares of Kymera Therapeutics common stock, with an estimated aggregate market value of approximately $8.4 million. The shares derive from stock option exercises and restricted stock unit vesting, and the filing adds to a pattern of recent insider selling totaling $10.0M over the past 30 days.
Key Facts
- Bruce N. Jacobs, an officer of Kymera Therapeutics, filed Form 144 on 06/30/2026 indicating intent to sell 77,109 shares.
- Estimated aggregate market value of the proposed sale is $8,429,555.88 based on the filing date.
- Shares to be sold consist of 61,378 from stock option exercises and 15,731 from restricted stock unit vesting.
- Recent insider activity shows 7 sells totaling $10.0M in the last 30 days, adding to this selling trend.
Financial Impact
Proposed sale of ~$8.4M in shares, representing approximately 0.09% of Kymera's $9.4B market cap.
Risk Factors
- Insider selling may indicate a lack of confidence in near-term prospects or a desire to diversify.
- Additional insider sales could follow, increasing supply and weighing on the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006647 |
| Document: 0001950047-26-006647-index.html | 0001950047-26-006647 |
| Document: 0001950047-26-006647.txt | 0001950047-26-006647 |
Track record
37 reports on KYMR
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers